

SKYEPHARMA PLC
Form 6-K
February 14, 2007

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

14th FEBRUARY 2007

**SKYEPHARMA TO PRESENT AT 19th ANNUAL ROTH CAPITAL
PARTNERS GROWTH STOCK CONFERENCE**

LONDON, UK, 14 February 2007-- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today that the Company's Chief Executive Officer, Frank Condella, will make a presentation at the 19th Annual Roth Capital Partners Growth Stock Conference in California, USA. Mr. Condella will deliver his presentation on Wednesday 21 February 2007 at 9.30 p.m. (GMT). Investors may access a live webcast of the presentation at www.skyepharma.com under the Investor Relations tab. The presentation will be archived for 3 months.

For further information please contact:

SkyePharma PLC

+44 207 491 1777

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director

Buchanan Communications

+44 207 466 5000

Tim Anderson / Mark Court / Rebecca Skye Dietrich

The Trout Group

+ 1 617 583 1308

Seth Lewis

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has nine approved products in the areas of oral, inhalation and topical delivery that are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ John Murphy

Name: John Murphy
Title: Company Secretary

Date: February 14, 2007